Vanguard Group’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$8.89B Buy
22,856,898
+704,790
+3% +$274M 0.14% 120
2025
Q1
$9.64B Buy
22,152,108
+666,534
+3% +$290M 0.17% 100
2024
Q4
$7.93B Buy
21,485,574
+138,380
+0.6% +$51M 0.14% 116
2024
Q3
$11.1B Buy
21,347,194
+140,269
+0.7% +$72.9M 0.2% 84
2024
Q2
$11.5B Sell
21,206,925
-24,784
-0.1% -$13.4M 0.22% 75
2024
Q1
$11B Buy
21,231,709
+4,519
+0% +$2.34M 0.22% 74
2023
Q4
$10B Buy
21,227,190
+23,807
+0.1% +$11.2M 0.22% 79
2023
Q3
$9.23B Sell
21,203,383
-131,330
-0.6% -$57.2M 0.23% 72
2023
Q2
$9.48B Sell
21,334,713
-137,867
-0.6% -$61.3M 0.22% 75
2023
Q1
$9.87B Sell
21,472,580
-864
-0% -$397K 0.25% 69
2022
Q4
$11B Buy
21,473,444
+239,661
+1% +$123M 0.3% 60
2022
Q3
$9.65B Buy
21,233,783
+183,370
+0.9% +$83.3M 0.28% 58
2022
Q2
$10.2B Buy
21,050,413
+277,518
+1% +$134M 0.29% 61
2022
Q1
$10.2B Buy
20,772,895
+1,860,427
+10% +$914M 0.24% 70
2021
Q4
$8.77B Sell
18,912,468
-15,598
-0.1% -$7.23M 0.2% 83
2021
Q3
$7.06B Buy
18,928,066
+17,645
+0.1% +$6.58M 0.18% 95
2021
Q2
$7.22B Buy
18,910,421
+65,981
+0.4% +$25.2M 0.18% 91
2021
Q1
$6.76B Sell
18,844,440
-110,134
-0.6% -$39.5M 0.18% 91
2020
Q4
$6.09B Sell
18,954,574
-375,159
-2% -$120M 0.18% 96
2020
Q3
$5.19B Sell
19,329,733
-321,519
-2% -$86.4M 0.17% 99
2020
Q2
$5.17B Sell
19,651,252
-354,942
-2% -$93.3M 0.18% 94
2020
Q1
$4.54B Buy
20,006,194
+495,707
+3% +$113M 0.19% 95
2019
Q4
$5.89B Sell
19,510,487
-4,911
-0% -$1.48M 0.2% 86
2019
Q3
$4.69B Buy
19,515,398
+44,613
+0.2% +$10.7M 0.17% 102
2019
Q2
$5.49B Buy
19,470,785
+146,654
+0.8% +$41.4M 0.21% 84
2019
Q1
$5.55B Buy
19,324,131
+196,086
+1% +$56.3M 0.22% 81
2018
Q4
$5.02B Buy
19,128,045
+398,571
+2% +$105M 0.23% 79
2018
Q3
$5.13B Buy
18,729,474
+532,579
+3% +$146M 0.2% 87
2018
Q2
$4.33B Buy
18,196,895
+216,648
+1% +$51.6M 0.18% 98
2018
Q1
$3.95B Buy
17,980,247
+176,665
+1% +$38.8M 0.17% 106
2017
Q4
$4.01B Sell
17,803,582
-174,025
-1% -$39.2M 0.18% 104
2017
Q3
$3.41B Buy
17,977,607
+172,881
+1% +$32.8M 0.16% 120
2017
Q2
$3.35B Buy
17,804,726
+479,046
+3% +$90.1M 0.17% 117
2017
Q1
$2.87B Buy
17,325,680
+700,705
+4% +$116M 0.15% 129
2016
Q4
$2.39B Buy
16,624,975
+232,327
+1% +$33.4M 0.13% 144
2016
Q3
$2.05B Buy
16,392,648
+401,294
+3% +$50.3M 0.12% 162
2016
Q2
$2.1B Buy
15,991,354
+386,213
+2% +$50.7M 0.13% 150
2016
Q1
$2.17B Buy
15,605,141
+491,837
+3% +$68.4M 0.14% 135
2015
Q4
$2.11B Buy
15,113,304
+270,474
+2% +$37.7M 0.14% 138
2015
Q3
$2.08B Buy
14,842,830
+38,454
+0.3% +$5.38M 0.15% 125
2015
Q2
$2.43B Buy
14,804,376
+58,018
+0.4% +$9.52M 0.16% 113
2015
Q1
$2.28B Buy
14,746,358
+346,790
+2% +$53.5M 0.15% 121
2014
Q4
$1.81B Buy
14,399,568
+215,000
+2% +$27M 0.13% 152
2014
Q3
$1.7B Buy
14,184,568
+93,620
+0.7% +$11.2M 0.13% 148
2014
Q2
$1.52B Buy
14,090,948
+118,103
+0.8% +$12.7M 0.12% 166
2014
Q1
$1.39B Sell
13,972,845
-238,289
-2% -$23.7M 0.12% 167
2013
Q4
$1.31B Buy
14,211,134
+109,355
+0.8% +$10.1M 0.12% 164
2013
Q3
$1.18B Buy
14,101,779
+462,841
+3% +$38.7M 0.12% 167
2013
Q2
$1.12B Buy
+13,638,938
New +$1.12B 0.12% 156